![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Bright Minds Biosciences Inc | NASDAQ:DRUG | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.0525 | -4.81% | 1.04 | 1.04 | 1.05 | 1.08 | 0.99 | 1.08 | 6,921 | 19:55:29 |
“In his short tenure on the Board, Doug’s scientific, clinical, and medical experience has proven invaluable in supporting our efforts to develop the next generation of safe and efficacious drugs for challenging brain disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. We wish him well in his new endeavors,” stated Ian McDonald, CEO and Co-founder of Bright Minds Biosciences.
“It has been an honor to serve on the Bright Minds Board. While I am stepping down from this role, I look forward to following the Company’s future progress as it works to create novel therapeutics to improve patient lives,” said Dr. Doug Williamson.
About Bright Minds
Bright Minds is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. Bright Minds has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The Company leverages its world-class scientific and drug development expertise to bring forward the next generation of safe and efficacious drugs. Bright Minds’ drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
Investor Contact:Lisa WilsonE: lwilson@insitecony.comT: 917-543-9932
Ian McDonaldCEO and DirectorE: ian@brightmindsbio.comT: 647 407 2515
1 Year Bright Minds Biosciences Chart |
1 Month Bright Minds Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions